Media Center

All news News

  • 19 September 2017

    Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

    Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share. This includes the exercise in full by the underwriter of its option to purchase up to 1,400,000 additional shares of common stock. The offering was led by Bain Capital Life Sciences with participation from new and existing investors, raising gross proceeds of approximately $40.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

  • 15 September 2017

    Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the pricing of an underwritten public offering of 9,333,334 shares of common stock for a public offering price of $3.75 per share. The gross proceeds from the offering are expected to be $35 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. 

  • 14 September 2017

    Marinus Pharmaceuticals Announces Public Offering of Common Stock

    Marinus Pharmaceuticals Announces Public Offering of Common Stock

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • 11 September 2017

    Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone

    Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), today announced that top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial. Oral ganaxolone, in addition to baseline treatment, showed a sizable and durable seizure-frequency reduction in the majority of patients, with some achieving an increase in the number of seizure-free days and reporting behavioral benefits. 

  • 06 September 2017

    Liquid Biopsy Tumor Heterogeneity Test Predicts Resistance to Targeted Therapy in Metastatic Prostate Cancer Patients

    Liquid Biopsy Tumor Heterogeneity Test Predicts Resistance to Targeted Therapy in Metastatic Prostate Cancer Patients

    Researchers at Epic Sciences and Memorial Sloan Kettering developed and applied a ground-breaking new test for measuring the cellular diversity within tumors, or tumor heterogeneity, through the analysis of single circulating tumor cells (CTCs). To measure tumor heterogeneity, researchers analyzed protein and morphology based biomarkers in single CTCs and quantified degrees of variance among CTCs in blood samples from patients prior to receiving targeted androgen receptor signaling inhibitor (ARSi) therapies, including the blockbuster drugs Zytiga® and Xtandi®, compared to blood samples from patients prior to receiving chemotherapy.

  • 06 September 2017

    ReVision Optics Names Two Ophthalmic Experts as Medical Monitors to Oversee Raindrop Near Vision Inlay Clinical Performance

    ReVision Optics Names Two Ophthalmic Experts as Medical Monitors to Oversee Raindrop Near Vision Inlay Clinical Performance

    ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that Bret Fisher, M.D. and Sumit (Sam) Garg, M.D. will serve as co-medical monitors to oversee the clinical performance of the Company’s Raindrop® Near Vision Inlay, a novel corneal inlay for the surgical correction of presbyopia approved by the U.S. Food and Drug Administration (FDA) in June 2016. Drs. Fisher and Garg are assuming the responsibilities previously handled by Roger F. Steinert, M.D., who passed away on June 6, 2017, and Douglas D. Koch, M.D., Professor and Allen, Mosbacher, and Law Chair of the Ophthalmology Department at Baylor College of Medicine in Houston.

  • 29 August 2017

    "Venture capital, is it obsolete today? I do not think so.." Author's column of Maxim Gorbachev

    "Venture capital, is it obsolete today? I do not think so.." Author's column of Maxim Gorbachev

    Maxim Gorbachev, Managing Partner of RMI Partners: "New technologies make dramatic changes to business. They even reached financing of venture capital companies. Use of crypto-currency has resulted into development of the new mechanism of crowdfunding – Initial Coin Offering (ICO) which is in a way similar to public share placement (IPO). Venture projects utilize blockchain technologies to create and sell digital tokens, thus raising funds from investors. When initially ICO was used as mechanism to develop new crypto-currency instruments such as Ethereum, nowadays ICO serve as a democratic mechanism of fund raising for any project. And this instrument cannot be ignored due to amounts of funds raised this way."   

  • 14 August 2017

    Innovate UK awards Atlas Genetics £2m SBRI phase II Contract

    Innovate UK awards Atlas Genetics £2m SBRI phase II Contract

    Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded a two year Innovate UK phase II contract to expand the Sexually Transmitted Infection (STI) test menu for the io® rapid diagnostic platform and support its adoption into UK sexual health clinics.

  • 10 August 2017

    Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended  June 30, 2017 . In addition, the Company provided a clinical and business update. As of  June 30, 2017 , Syndax had  $130.0 million  in cash, cash equivalents and short-term investments.

  • 09 August 2017

    Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter and six months ended June 30, 2017 and provided an update on its development programs.

All publications Media about us